174
Participants
Start Date
May 3, 2019
Primary Completion Date
October 28, 2022
Study Completion Date
October 28, 2022
AR-301
AR-301 (tosatoxumab) 20 mg/kg administered once intravenously the day of enrolment.
Placebo
Placebo comparator
BEL-05, Ottignies
GEO-06, Gori
ZAF-09, Johannesburg
GEO-01, Kutaisi
GEO-03, Kutaisi
GEO-04, Kutaisi
GEO-10, Kutaisi
BEL-01, Lodelinsart
EST-01, Tallinn
FRA-18, Brive-la-Gaillarde
ESP-01, Madrid
ISR-04, Haifa
TUR-06, Istanbul
FRA-11, Rennes
FRA-01, Nantes
MEX-07, Guadalajara
FRA-16, Orléans
UKR-05, Chernivtsi
TUR-01, Trabzon
UKR-02, Kharkiv
UKR-09, Kharkiv
FRA-02, Strasbourg
FRA-10, Bron
UKR-03, Ivano-Frankivsk
FRA-05, La Roche-sur-Yon
FRA-04, Limoges
FRA-13, Trévenans
RUS-16, Zhukovskiy
RUS-18, Arkhangelsk
RUS-02, Saint Petersburg
RUS-10, Smolensk
BLR-01, Minsk
BLR-06, Grodno
BLR-04, Homyel
RUS-11, Chelyabinsk
CHN-09, Guangzhou
RUS-04, Novosibirsk
RUS-01, Krasnoyarsk
ISR-01, Ramat Gan
BRA-08, Curitiba
BRA-04, Curitiba
GEO-02, Tbilisi
GEO-09, Tbilisi
GEO-07, Tbilisi
LVA-02, Riga
Lead Sponsor
Aridis Pharmaceuticals, Inc.
INDUSTRY